A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0mg/kg) in the Reduction of Clinical Asthma Exacerbations and Change in Lung Function in Patients (12-75 years of age)

Grants and Contracts Details

StatusFinished
Effective start/end date4/26/11 → 3/31/15

Funding

  • Cephalon Inc: $31,220.00